Shareholder Derivative

MANHATTAN — Shareholders say in a federal derivative complaint that directors of Ophthotech Corp. overhyped the prospects of their experimental macular degeneration drug Fovista, whose failure whacked 86 percent off the share prices, erasing nearly $1.2 billion in market capitalization.

%d bloggers like this: